Eagle Pharmaceuticals Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 134

Employees

  • Stock Symbol
  • EGRX

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $0.90
  • (As of Friday Closing)

Eagle Pharmaceuticals General Information

Description

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advance stages of development and is under review for approval by the Food and Drug Administration.

Contact Information

Website
www.eagleus.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 50 Tice Boulevard
  • Suite 315
  • Woodcliff Lake, NJ 07677
  • United States
+1 (201)
Primary Industry
Drug Discovery
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 50 Tice Boulevard
  • Suite 315
  • Woodcliff Lake, NJ 07677
  • United States
+1 (201)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eagle Pharmaceuticals Stock Performance

As of 13-Nov-2026, Eagle Pharmaceuticals’s stock price is $0.90. Its current market cap is $11.8M.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.90 $0.82 $11.8M 3.98K

Eagle Pharmaceuticals Financials Summary

As of 30-Jun-2023, Eagle Pharmaceuticals has a trailing 12-month revenue of $258M.

In Thousands,
USD
TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 310,515 429,843 589,570 556,111
Revenue 257,551 316,610 171,546 187,802
EBITDA 55,603 77,231 287 28,230
Net Income 11,948 35,642 (8,627) 11,989
Total Assets 404,822 406,160 253,732 253,190
Total Debt 71,615 64,000 26,916 34,258
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eagle Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eagle Pharmaceuticals‘s full profile, request access.

Request a free trial

Eagle Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Eagle Pharmaceuticals‘s full profile, request access.

Request a free trial

Eagle Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable prod
Drug Discovery
Woodcliff Lake, NJ
134 As of 2022

Darmstadt, Germany
 

Saint Laurent, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eagle Pharmaceuticals Competitors (24)

One of Eagle Pharmaceuticals’s 24 competitors is Merck, a Corporation company based in Darmstadt, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck Corporation Darmstadt, Germany
Nymox Pharmaceutical Corporation Saint Laurent, Canada
Biocon Formerly PE-Backed Bengaluru, India
Cipla Corporation Mumbai, India
Vicore Pharma Holding Formerly VC-backed Stockholm, Sweden
You’re viewing 5 of 24 competitors. Get the full list »

Eagle Pharmaceuticals Patents

Eagle Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024326051-A1 Use of remimazolam for pediatric sedation Pending 11-Aug-2023
EP-4757802-A2 Use of remimazolam for pediatric sedation Pending 11-Aug-2023
WO-2025038446-A2 Use of remimazolam for pediatric sedation Inactive 11-Aug-2023
WO-2025038446-A3 Use of remimazolam for pediatric sedation Inactive 11-Aug-2023
JP-2026015586-A Pemetrexed formulation Pending 05-Oct-2020
To view Eagle Pharmaceuticals’s complete patent history, request access »

Eagle Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eagle Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Eagle Pharmaceuticals‘s full profile, request access.

Request a free trial

Eagle Pharmaceuticals Investments & Acquisitions (5)

Eagle Pharmaceuticals’s most recent deal was a Early Stage VC with Enalare for . The deal was made on 09-Aug-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Enalare 09-Aug-2022 Early Stage VC Drug Discovery
Acacia Pharma 09-Jun-2022 Merger/Acquisition Pharmaceuticals
Tyme Technologies 07-Jan-2020 PIPE Biotechnology
Arsia Therapeutics 16-Nov-2016 Merger/Acquisition Drug Delivery
Karalex Pharma 31-Dec-2008 Merger/Acquisition Pharmaceuticals
To view Eagle Pharmaceuticals’s complete investments and acquisitions history, request access »

Eagle Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated September, 30, 2025

28.04 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,999

Rank

Percentile

Pharmaceuticals

Industry

of 952

Rank

Percentile

Biotechnology

Subindustry

of 444

Rank

Percentile

To view Eagle Pharmaceuticals’s complete esg history, request access »

Eagle Pharmaceuticals Exits (2)

Eagle Pharmaceuticals’s most recent exit was on 07-Jan-2020 from Tyme Technologies. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Tyme Technologies 07-Jan-2020 Completed
  • 2 buyers
Karalex Pharma 31-Dec-2008 Merger/Acquisition Completed
To view Eagle Pharmaceuticals’s complete exits history, request access »

Eagle Pharmaceuticals Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Acacia Pharma Cambridge, United Kingdom 2007

Eagle Pharmaceuticals FAQs

  • When was Eagle Pharmaceuticals founded?

    Eagle Pharmaceuticals was founded in 2007.

  • Where is Eagle Pharmaceuticals headquartered?

    Eagle Pharmaceuticals is headquartered in Woodcliff Lake, NJ.

  • What is the size of Eagle Pharmaceuticals?

    Eagle Pharmaceuticals has 134 total employees.

  • What industry is Eagle Pharmaceuticals in?

    Eagle Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Eagle Pharmaceuticals a private or public company?

    Eagle Pharmaceuticals is a Public company.

  • What is Eagle Pharmaceuticals’s stock symbol?

    The ticker symbol for Eagle Pharmaceuticals is EGRX.

  • What is the current stock price of Eagle Pharmaceuticals?

    As of 13-Nov-2026 the stock price of Eagle Pharmaceuticals is $0.90.

  • What is the current market cap of Eagle Pharmaceuticals?

    The current market capitalization of Eagle Pharmaceuticals is $11.8M.

  • What is Eagle Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Eagle Pharmaceuticals is $258M.

  • Who are Eagle Pharmaceuticals’s competitors?

    Merck, Nymox Pharmaceutical, Biocon, Cipla, and Vicore Pharma Holding are some of the 24 competitors of Eagle Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process